KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Depreciation & Amortization (CF) (2020 - 2025)

Ginkgo Bioworks Holdings' Depreciation & Amortization (CF) history spans 6 years, with the latest figure at $13.7 million for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) fell 12.71% year-over-year to $13.7 million; the TTM value through Dec 2025 reached $59.0 million, down 6.4%, while the annual FY2025 figure was $59.0 million, 6.39% down from the prior year.
  • Depreciation & Amortization (CF) reached $13.7 million in Q4 2025 per DNA's latest filing, down from $14.2 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $21.1 million in Q3 2023 to a low of $5.6 million in Q1 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $13.2 million, with a median of $13.9 million recorded in 2025.
  • Peak YoY movement for Depreciation & Amortization (CF): soared 136.18% in 2023, then crashed 32.12% in 2024.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $8.0 million in 2021, then surged by 95.76% to $15.7 million in 2022, then dropped by 18.06% to $12.8 million in 2023, then increased by 21.93% to $15.7 million in 2024, then fell by 12.71% to $13.7 million in 2025.
  • Per Business Quant, the three most recent readings for DNA's Depreciation & Amortization (CF) are $13.7 million (Q4 2025), $14.2 million (Q3 2025), and $15.8 million (Q2 2025).